AB 575 California Assembly · 2025-2026 Regular Session

Obesity Prevention Treatment Parity Act.

Summary
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act's requirements a crime. Existing law provides for the regulation of disability and health insurers by the Department of Insurance. Existing law sets forth specified coverage requirements for plan contracts and insurance policies. This bill, the Obesity Prevention Treatment Parity Act, would require an individual or group health care service plan contract or health insurance policy that provides coverage for outpatient prescription drug benefits, as specified, and is issued, amended, or renewed on or after January 1, 2026, to include coverage for at least one specified anti-obesity medication and intensive behavioral therapy for the treatment of obesity without prior authorization. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.
Bill status failed 1 of 4 stages cleared
Introduction
Feb 2025
Committee Review
Floor Vote
Governor
Introduced Feb 12, 2025 Last action Feb 2, 2026
Maddy AI version diff · 2 comparisons

What changed between versions

02/12/25 - Introduced 03/12/25 - Amended Assembly · 3 edits · Mar 12, 2025
MINOR
The amendment adds a new phrase specifying that coverage must include 'glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment or prevention of obesity,' potentially expanding coverage to GLP-1RA medications used for prevention rather than only treatment. It also refines the definition of GLP-1RAs by adding a singular term and changing the language from 'a class' to 'one of a class.' The digest was updated to say 'at least one specified anti-obesity medication.'
Scope change
The bill's scope may have expanded slightly by explicitly including GLP-1RA medications used for prevention of obesity, not just treatment, and by adding a singular definition for the drug class.
SCOPE

Added the phrase 'glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment or prevention of obesity' to the coverage requirement in both the Health Care Service Plan section and the Insurance Code section, potentially expanding covered uses from treatment only to include prevention.

The legislative digest was updated from 'at least one anti-obesity medication' to 'at least one specified anti-obesity medication,' adding the qualifier 'specified.'

DEFINITION

The definition of GLP-1RAs was revised to add a singular term 'glucagon-like peptide-1 receptor agonist (GLP-1RA)' defined as 'one of a class of medications that helps lower blood sugar levels and promote weight loss,' replacing the prior simpler definition.

Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
8
Key actions
3
Committee
5
Amendments
1
Feb 2, 2026
Lower · Passed
From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
lower
Apr 28, 2025
Lower · Passed
In committee: Set, first hearing. Hearing canceled at the request of author.
lower
Mar 13, 2025
Committee
Re-referred to Com. on HEALTH.
lower
Mar 12, 2025
Introduced
From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
lower
Feb 24, 2025
Committee
Referred to Com. on HEALTH.
lower
Feb 13, 2025
Lower · Passed
From printer. May be heard in committee March 15.
lower
1 primary · 0 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Joaquin Arambula
Joaquin Arambula
DDemocratic
CA
31